Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Analgesic

or Antidepressant

or [[:Category:Tryptamines|Tryptamine]]

Use the filters below to narrow your results.

Agomelatine (1) · Amoxapine (1) · Buprenorphine (1) · Butorphanol (1) · Clomipramine (1) · Codeine (2) · Desipramine (1) · Dextropropoxyphene (1) · Dihydrocodeine (1) · DMT (1) · Duloxetine (1) · Ethylmorphine (1) · Fentanyl (1) · Hydrocodone (1) · Hydromorphone (1) · Imipramine (1) · Isocarboxazid (1) · Levomilnacipran (1) · Levorphanol (1) · Maprotiline (1) · Meperidine (1) · Methadone (1) · Milnacipran (1) · Moclobemide (1) · Nalbuphine (1) · Nefazodone (1) · Oxymorphone (1) · Papaverine (1) · Pentazocine (1) · Phenelzine (1) · Protriptyline (1) · Psilocybin (1) · Reboxetine (1) · Sertraline (1) · Tapentadol (1) · Tianeptine (1) · Tranylcypromine (1) · Trimipramine (1)

None (7) · (multiple, generic dominant) (1) · Anafranil (1) · Aurorix (1) · COMP360 (Compass Pathways, investigational synthesized clinical formulation) (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Dolophine (1) · Duragesic (1) · Edronax (1) · Fetzima (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Norpramin (1) · Nubain (1) · Nucynta (1) · Opana (1) · Parnate (1) · Savella (1) · Serzone (1) · Stablon (1) · Stadol (1) · Suboxone (1) · Surmontil (1) · Talwin (1) · Tofranil (1) · Valdoxan (1) · Vicodin (1) · Vivactil (1) · Zoloft (1)

5-HT2A partial agonist; sigma-1 agonist (1) · Irreversible non-selective MAO inhibitor (3) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; NMDA antagonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Partial mu-opioid agonist; kappa antagonist (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Potent serotonin reuptake inhibitor; also NRI (1) · Prodrug to [[Psilocin|psilocin]] (4-hydroxy-N,N-dimethyltryptamine), a partial agonist at the [[Receptor:5-HT2A|5-HT2A]] serotonin receptor; the action that defines the classical-psychedelic mechanism (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Reversible inhibitor of MAO-A (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1)

None (36) · (investigational) '"`UNIQ--vote-000000EF-QINU`"', '"`UNIQ--vote-000000F0-QINU`"', '"`UNIQ--vote-000000F1-QINU`"', '"`UNIQ--vote-000000F2-QINU`"', '"`UNIQ--vote-000000F3-QINU`"' (1) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Mild to moderate pain; cough suppression (low-dose). (1)

None (36) · 25 mg (1) · Adult: 15–60 mg every 4 hours as needed. (1) · Modern clinical-trial standard: 25 mg synthesized psilocybin, single oral dose with psychological support (1)

None (36) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · Synthesized psilocybin capsules (COMP360 and other investigational formulations); dried whole [[Psilocybe|Psilocybe]] mushrooms (variable potency, no legal supply chain in most jurisdictions); psilocybin truffles (Psilocybe sclerotia, legal in the Netherlands) (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (36) · 200 mg/d (1) · 360 mg/day (1) · Not FDA-approved; clinical-trial protocols use up to 30 mg in adult investigational dosing (1)

None (35) · Oral (3) · PO (only formulation marketed in the US). (1)

None (35) · 20-45 min subjective onset; psilocin formation from psilocybin requires intestinal and hepatic alkaline phosphatase (1) · 30–60 min (PO) (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)

None (34) · 4-6 hours (1) · 4–6 hours (1) · About 20 minutes (1) · Chronic daily dosing (1) · Long (1)

None (34) · 2.5–3 hours (1) · 9–12 minutes (intravenous) (1) · Psilocin: ~2-3 h; psilocybin itself is a prodrug, dephosphorylated within minutes of absorption (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

None (35) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · Oral bioavailability of psilocin from administered psilocybin approximately 50% (1) · ~50% (highly variable) (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (35) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Not studied in human pregnancy; no approved clinical use in any population (1)

None (35) · Rx-only (1) · Rx-only in US (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)